The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-(2-((1-Methylpiperidin-2-yl)methoxy)-4-(4-(vinylsulfonyl)piperazin-1-yl)thieno[2,3-d]pyrimidin-6-yl)-benzonitrile ID: ALA4860067
PubChem CID: 164611537
Max Phase: Preclinical
Molecular Formula: C26H30N6O3S2
Molecular Weight: 538.70
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: C=CS(=O)(=O)N1CCN(c2nc(OCC3CCCCN3C)nc3sc(-c4ccc(C#N)cc4)cc23)CC1
Standard InChI: InChI=1S/C26H30N6O3S2/c1-3-37(33,34)32-14-12-31(13-15-32)24-22-16-23(20-9-7-19(17-27)8-10-20)36-25(22)29-26(28-24)35-18-21-6-4-5-11-30(21)2/h3,7-10,16,21H,1,4-6,11-15,18H2,2H3
Standard InChI Key: ZTOVLKZSIBADQB-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 41 0 0 0 0 0 0 0 0999 V2000
16.2987 -1.9419 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.1244 -1.9419 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
16.7094 -1.2262 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.1244 -2.7677 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.4148 -3.1826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4148 -4.0083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.1280 -4.4191 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.8413 -4.0083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8413 -3.1826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.1280 -5.2440 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4103 -5.6542 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.4103 -6.4791 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.1261 -6.8949 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.8411 -6.4733 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8411 -5.6519 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.6206 -5.3939 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.1058 -6.0557 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.6301 -6.7203 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
19.9284 -6.0557 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3478 -6.7659 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.1728 -6.7659 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.5793 -6.0412 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.1589 -5.3262 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3354 -5.3262 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8438 -1.5269 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8438 -0.7012 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.3980 -6.0287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.2194 -6.0203 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.6983 -6.8889 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
14.9873 -6.4772 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1901 -7.7112 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.2753 -6.8871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6080 -6.4040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8512 -6.7397 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7660 -7.5638 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4375 -8.0521 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8566 -8.1914 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 2 1 0
5 4 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 1 0
9 4 1 0
7 10 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
15 14 2 0
15 10 1 0
16 15 1 0
17 16 2 0
18 17 1 0
14 18 1 0
17 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 19 1 0
2 25 1 0
25 26 2 0
27 28 3 0
22 27 1 0
12 29 1 0
29 30 1 0
32 30 1 0
31 32 1 0
31 36 1 0
32 33 1 0
33 34 1 0
34 35 1 0
35 36 1 0
31 37 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 538.70Molecular Weight (Monoisotopic): 538.1821AlogP: 3.69#Rotatable Bonds: 7Polar Surface Area: 102.66Molecular Species: NEUTRALHBA: 9HBD: ┄#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 8.47CX LogP: 4.25CX LogD: 3.14Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.45Np Likeness Score: -1.40
References 1. Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L.. (2021) Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer., 64 (16.0): [PMID:34351741 ] [10.1021/acs.jmedchem.1c00678 ]